文献速递血栓与止血

艾曲泊帕治疗中国成人慢性原发免疫性血小板减少症的疗效与安全性

[The efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2018-01-01

该随机、单中心、6周、安慰剂对照研究纳入35例中国成人慢性原发免疫性血小板减少症(cITP)患者,艾曲泊帕组17例、安慰剂组18例。结果显示艾曲泊帕组在治疗2周内及第6周血小板计数达标率均高于安慰剂组,需要补救治疗的比例低于安慰剂组,但转氨酶增高、胆红素增高及脑梗死等不良事件更常见。

要点

  • 治疗2周内艾曲泊帕组PLT≥30×10(9)/L比例为64.71%,高于安慰剂组的27.78%(P=0.031)。
  • 治疗第6周艾曲泊帕组PLT≥50×10(9)/L比例为64.71%,高于安慰剂组的11.11%(P=0.001)。
  • 安慰剂组8例(44.44%)需增加合并用药,艾曲泊帕组无增加合并用药病例(P=0.002)。

核心结论

  • 艾曲泊帕治疗成人慢性ITP起效时间较快且具有良好的安全性。
  • 血小板生成素受体激动剂艾曲泊帕是中国成人cITP的合适治疗选择。

研究设计与样本

  • 随机、单中心、6周、安慰剂对照研究,2013年1月29日至2014年5月16日纳入35例成人cITP患者。
  • 艾曲泊帕组17例(起始剂量25 mg/d),安慰剂组18例;艾曲泊帕组1例因不良事件退组并停止治疗。

主要发现

  • 35例患者中男6例、女29例,中位年龄42(22~66)岁。
  • 治疗开始2周内PLT≥30×10(9)/L的患者比例:艾曲泊帕组64.71%(11/17)vs 安慰剂组27.78%(5/18),P=0.031。
  • 治疗第6周PLT≥50×10(9)/L的患者比例:艾曲泊帕组64.71%(11/17)vs 安慰剂组11.11%(2/18),P=0.001;PLT≥30×10(9)/L的患者比例:艾曲泊帕组76.47%(13/17)vs 安慰剂组38.89%(7/18),P=0.028。
  • 6周治疗期内至少1次PLT≥50×10(9)/L的患者比例:艾曲泊帕组94.11%(16/17)vs 安慰剂组33.33%(6/18),P<0.001;50%时间PLT≥50×10(9)/L的患者比例:艾曲泊帕组70.59%(12/17)vs 安慰剂组11.11%(2/18),P<0.001。
  • 需补救治疗的患者比例:安慰剂组44.44%(8/18)vs 艾曲泊帕组无(P=0.002)。治疗第6周WHO出血分级两组差异无统计学意义(P=0.066)。

关键数值与推荐

  • 艾曲泊帕组与艾曲泊帕可能相关的不良事件包括转氨酶增高3/17、胆红素增高5/17、血小板升高相关脑梗死1/17。

临床怎么用

  • 作者认为艾曲泊帕是中国成人cITP的合适治疗选择,治疗期间需关注转氨酶增高、胆红素增高及脑梗死等不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the safety and efficacy of eltrombopag for adult patients with chronic immune thrombocytopenia (cITP). Methods: It was a randomised, single-centre, 6 weeks, placebo-controlled study. Beginning in January 29(th), 2013, 35 patients were enrolled, and the trial was completed on May 16(th), 2014. 17 patients were assigned to receive eltrombopag (starting dose 25 mg/d) and 18 were assigned to receive placebo. Results: A total of 35 cases of adult cITP, 6 males and 29 females with a median age of 42(22-66) years were enrolled. One patient withdrew from eltrombopag treatment group for the adverse event (AE) and discontinued treatment. In first two weeks, 27.78% (5/18) of placebo-treated compared with 64.71%(11/17) of eltrombopag-treated patients achieved platelet counts ≥ 30×10(9)/L(P=0.031); Treatment 6 weeks, the proportion of platelet counts reached ≥50×10(9)/L and ≥ 30×10(9)/L in eltrombopag-treated were higher than placebo-treated ones with statistically significant differences in both groups [64.71%(11/17) vs 11.11% (2/18), P=0.001; 76.47% (13/17) vs 38.89% (7/18), P=0.028]; The study also indicated a statistically significant difference in favour of eltrombopag compared with placebo in the odds of achieving the outcome of a platelet count ≥ 50×10(9)/L at least once during 6-week treatment (94.11% vs 33.33%, P<0.001), and 70.59%(12/17) of patients with the platelet count continuously ≥ 50×10(9)/L in 50% of treatment time in eltrombopag-treated group was more than placebo-treated one [11.11%(2/18), P<0.001]. Proportions of patients who required rescue treatment were 44.44% in placebo group and none in eltrombopag-treated one, respectively (P=0.002); The odds of bleeding symptoms with the WHO bleeding scale had no difference in both groups after 6 weeks (P=0.066). Adverse events that occurred more frequently due to eltrombopag than placebo included increased transaminase (3/17) and blood bilirubin (5/17), cerebral infarction(1/17). Conclusions: The thrombopoietin receptor agonist eltrombopag was a suitable therapeutic option for Chinese adults with cITP. 目的: 观察艾曲泊帕治疗成人慢性原发免疫性血小板减少症(ITP)的疗效及安全性。 方法: 2013年1月29日至2014年5月16日,纳入35例慢性ITP患者进行随机、双盲、安慰剂对照临床研究,以25 mg/d为起始剂量给予艾曲泊帕(17例)或安慰剂(18例),疗程为6周。 结果: 35例慢性ITP患者中男6例、女29例,中位年龄42(22~66)岁。艾曲泊帕组退组1例,其余患者均完成治疗。艾曲泊帕组在治疗开始2周内PLT≥30×10(9)/L的患者百分比高于安慰剂组[64.71%(11/17)对27.78%(5/18),P=0.031]。治疗第6周,艾曲泊帕组PLT≥50×10(9)/L、PLT≥30×10(9)/L患者百分比均高于安慰剂组[64.71%(11/17)对11.11%(2/18),P=0.001;76.47%(13/17)对38.89%(7/18),P=0.028]。艾曲泊帕组6周治疗期内至少1次PLT≥50×10(9)/L、50%时间PLT≥50×10(9)/L的患者百分比均高于安慰剂组[94.11%(16/17)对33.33%(6/18),P<0.001;70.59%(12/17)对11.11%(2/18),P<0.001]。安慰剂组8例(44.44%)患者治疗期间增加合并用药,艾曲泊帕组无增加合并用药病例(P=0.002)。治疗第6周WHO出血分级比较:艾曲泊帕组16例均为0级(退组1例未评估),安慰剂组0、1级分别为14、4例,两组差异无统计学意义(P=0.066)。与艾曲泊帕可能相关的不良事件包括转氨酶增高3例、胆红素增高5例、血小板升高相关脑梗死1例。 结论: 艾曲泊帕治疗成人慢性ITP起效时间较快且具有良好的安全性。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Huang YT, Liu XF, Chen YF, et al. [The efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 29551030. doi:10.3760/cma.j.issn.0253-2727.2018.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。